Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-572P is classified as a **pseudogene** of the **U6 small nuclear RNA (snRNA)** gene family. U6 snRNA is essential in eukaryotic cells, where it forms part of the spliceosome—the complex responsible for the excision of introns from precursor mRNA during splicing[1][3]. Pseudogenes like RNU6-572P are characterized by high sequence similarity to the functional U6 genes but contain mutations or structural variations rendering them nonfunctional: they do not produce a functional RNA or protein product, nor do they participate in typical U6 snRNA roles in the spliceosome. The human genome contains many U6 pseudogenes, thought to be "back-ups" or relics from gene duplication and retrotransposition events[1][4]. While other pseudogenes have sometimes been found to modulate gene expression by acting as competitive endogenous RNAs (ceRNAs) or miRNA decoys, there is no published evidence to suggest RNU6-572P possesses any such regulatory activity or disease association[2]. RNU6-572P is **not a therapeutic target**: it does not encode a protein, is not a receptor or enzyme, and has no known pharmacological relevance. There are no known drugs, biomarkers, or safety concerns associated with this pseudogene. In sum, RNU6-572P is a non-coding RNA pseudogene, sometimes annotated in genomic databases but not functionally or clinically relevant.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on U6 small nuclear RNA 572, pseudogene (RNU6-572P).